CN103211869B - Traditional Chinese medicine eye drops used for treating acute conjunctivitis and preparation method thereof - Google Patents
Traditional Chinese medicine eye drops used for treating acute conjunctivitis and preparation method thereof Download PDFInfo
- Publication number
- CN103211869B CN103211869B CN2013101751855A CN201310175185A CN103211869B CN 103211869 B CN103211869 B CN 103211869B CN 2013101751855 A CN2013101751855 A CN 2013101751855A CN 201310175185 A CN201310175185 A CN 201310175185A CN 103211869 B CN103211869 B CN 103211869B
- Authority
- CN
- China
- Prior art keywords
- eye drop
- ethanol
- add
- group
- filter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a traditional Chinese medicine eye drops used for treating acute conjunctivitis and a preparation method thereof. The traditional Chinese medicine eye drops are processed and prepared from honeysuckle flower, mulberry leaf and wild chrysanthemum flower in certain proportion, have the effects of clearing away heat and toxic materials, eliminating red and reducing swelling and are applicable to treatment of the acute conjunctivitis. Compared with the prior art, the traditional Chinese medicine eye drops have the advantages that a process is advanced, a clinical pharmacodynamic experiment effect is more remarkable, biological availability is high and no toxic or side effect is produced.
Description
Technical field
The present invention relates to a kind of eyedrops for acute conjunctivitis and preparation method thereof, belong to technical field of traditional Chinese medicine pharmacy.
Technical background
Acute conjunctivitis is ophthalmology common disease, frequently-occurring disease, and its principal character is that onset is anxious, rapid onset, conjunctival congestion and mycopus sexual secretion, and eye has gargalesthesia, foreign body sensation, burn feeling etc.This disease is mainly in spring and autumn, and the reason caused mostly is due to antibacterial or viral infection.Drug therapy is mainly western medical treatment and Chinese traditional treatment at present; Western medical treatment mainly be take the medicines such as chloromycetin, rifampicin, ciprofloxacin as main, and these medicine side effect are more common, and what have also has serious untoward reaction, and body easily produces toleration, very unfavorable to people's health.The traditional Chinese medical science, aspect the treatment acute conjunctivitis, mainly be take Chinese patent medicine as main, oral medicine commonly used, and onset is slower, and cure rate is very low, easily recurrence.Seldom, curative effect is undesirable for the external application Chinese medicine eye drop, can not meet clinical needs.
Currently available technology, Chinese patent discloses that (publication number is: CN1943630A) prescription and the technique of " a kind of eye medicinal of preventing and treating conjunctivitis and keratitis and preparation method thereof ", the inventor is through years of researches, find that the preparation made by its technique exists: curative effect is undesirable, cure rate is low, easily recurrence; Technique is thicker, and certain toxic and side effects is arranged: eyes are red itches, poor stability, the defect such as active constituent content is low.For solving the existing defect of above-mentioned prior art, in the time in recent years, we are by excavating the abundant Chinese medicine resource of motherland, in conjunction with a large amount of Study on clinical pharmacodynamics, invented a kind of eyedrops for acute conjunctivitis, this product " gold leaf eye drop " is that (publication number is: CN1943630A) on the basis of technique at it, by a large amount of experiments, grope, discovery makes " extracting honeysuckle carries out percolation with ethanol " in its technique into that " extracting honeysuckle adds ethanol 100ml, soak and carry out percolation by appendix I0 percolation of Chinese Pharmacopoeia version in 2000 with 10 times of amounts of 75% ethanol in 24 hours ", and " adding ethanol to carry out precipitate with ethanol " in its technique made into to " secondary precipitate with ethanol: add for the first time ethanol to make to reach 65% containing alcohol amount, add for the second time ethanol to make to reach 75% containing the alcohol amount " it is rear that we have made eye drop according to new technology, with disclosing according to Chinese patent, (publication number is: the eye drop that CN1943630A) prescription of " a kind of eye medicinal of preventing and treating conjunctivitis and keratitis and preparation method thereof " and technique are prepared from is compared, its clinical pharmacodynamic experiment effect significantly improves, technique is more reasonable, effective ingredient content is high, safe without toxic side effect, eyes are without any discomfort.
Summary of the invention
The object of the invention is to for the existing defect of state of the art, by excavating the abundant Chinese medicine resource of motherland, in conjunction with a large amount of Study on clinical pharmacodynamics, a kind of prescription science, evident in efficacy is provided, and a kind of eyedrops for acute conjunctivitis that human body is had no side effect.
Another object of the present invention is to provide the preparation method of eyedrops of the present invention.
For achieving the above object, the technical solution used in the present invention is:
The present invention is for the eyedrops of acute conjunctivitis, and its formula consists of:
Flos Lonicerae 100g Folium Mori 30g Flos Chrysanthemi Indici 30g.
The present invention is as follows for the preparation method of the eyedrops of acute conjunctivitis:
Above three flavors, extracting honeysuckle adds ethanol 100ml, soak and within 24 hours, press appendix I0 percolation of Chinese Pharmacopoeia version in 2000, with 10 times of amounts of 75% ethanol, carry out percolation, percolation speed is 1～3ml/ minute. kilogram, collect percolate, residue pressed liquor and percolate merge, and standing 24 hours, filter, decompression recycling ethanol to 50 ℃ records relative density and is 1.1, standby, medicinal residues and Folium Mori, Flos Chrysanthemi Indici decocts with water twice, add for the first time 10 times of amounts of water, decoct 30 minutes, collect distillate 60-100ml, add for the second time 8 times of amounts of water, decoct 30 minutes, merge decocting liquid twice, filter, being concentrated into 25 ℃, to record relative density be 1.1-1.2, add ethanol to make to reach 65% containing the alcohol amount, cold preservation 24 hours, filter, it is 1.1 that filtrate recycling ethanol to 50 ℃ records relative density, add ethanol to make to reach 75% containing the alcohol amount, standing 24 hours, filter, it is 1.1 that filtrate recycling ethanol to 50 ℃ records relative density, merge extracted twice filtrate and distillate, add greening sodium 6g, ethyl hydroxybenzoate 0.2g, be stirred to dissolve, adding distil water is to 1000ml, reconciling pH with 5% sodium hydroxide solution is 6.5-7.5, add again 0.2% active carbon to boil 10 minutes, filter, packing, sterilizing, obtain eye drop.
The Pharmacodynamic test of active extract data:
The nomenclature of drug of Chinese medicine composition of the present invention is: the gold leaf eye drop.
The test medicine:
1, the present invention tests the preparation (gold leaf eye drop of the present invention) with medicine, and the gold leaf eye drop of the present invention of take is example, and specifically prescription and preparation technology are shown in embodiment 1.
2, contrast medicine (former invention eye drop group): disclose according to Chinese patent that (publication number is: CN1943630A) prepared by the prescription of the embodiment 1 of " a kind of eye medicinal of preventing and treating conjunctivitis and keratitis and preparation method thereof " and technique; Specific as follows:
Prescription: Flos Lonicerae 1000g Folium Mori 300g Flos Chrysanthemi Indici 300g
Add eye medicinal liquid preparation substrate to 10000ml
Preparation method:
A: extracting honeysuckle carries out percolation with ethanol, collects percolate, and standing 24 hours, filter, reclaim ethanol to relative density and be 1.1 (50 ℃), standby;
B: Flos Lonicerae residue, Folium Mori, the Flos Chrysanthemi Indici got after percolation add water, decoct, and filter, and repetitive operation 3 times, merge filtrate 3 times, and being concentrated into relative density is 1.1-1.2 (25 ℃), adds ethanol to carry out precipitate with ethanol, filter, and filtrate recycling ethanol, standby;
C: prepare eye medicinal preparation substrate: get water for injection, add pleasing to the eye isoosmotic adjusting agent, the preserved ophthalmic antibacterial used, be stirred to dissolve, filter filtrate for later use;
D: the filtrate that A and B are made is added in C filtrate, stirs, and benefit adds to the full amount of water for injection, and filters, and fill, make the clear and bright eye drop body preparation of water solublity.
Experiment purpose: by the pharmacological experiment study that improves the effects such as microcirculation, antiinflammatory, raising immunity of organisms and treatment conjunctiva inflammation to gold leaf eye drop of the present invention and former invention eye drop, gold leaf eye drop of the present invention and former invention eye drop are contrasted, observed the power of its pharmacological action.
Test method: gold leaf eye drop group of the present invention and the former invention eye drop group impact on rabbit eyes conjunctiva inflammation due to Oleum Tiglii; Impact on the rabbit eyes Bulbar conjunctiva microcirculation; The impact of xylol induced mice auricle edema; Impact on the mouse peritoneal capillary permeability; Impact on trinitro-chlorobenzene induced mice ear delayed hypersensitivity; Turnover of Mouse Peritoneal Macrophages is engulfed to the impact of chicken red blood cell ability.
One, on the impact of rabbit eyes conjunctiva inflammation due to Oleum Tiglii
Experiment material
1, animal: rabbit, male and female have concurrently, body weight 1.8～2.2kg.
2, medicine: former invention eye drop group; Large, medium and small three the dosage groups of gold leaf eye drop of the present invention.
Experimental technique
50 of rabbit, male and female half and half, body weight 1.8～2.2kg, be divided into 5 groups at random, 10 every group.Each group is all done the eye conjunctivitis moulding.Fixedly the rabbit head, pull open palpebra inferior, and every splashes into 10% Oleum Tiglii proinflammatory agent 150 μ l, makes it keep washing away with normal saline after 30s in the conjunctiva bag.Respectively at causing 1h, 3h after scorching moulding, 6h, 24h and 48h.Except model group splashes into normal saline 150 μ l/, all the other each groups splash into respectively eye drop, and large, medium and small three the dosage groups of gold leaf eye drop group of the present invention only splash into respectively administration 0.012,0.006,0.003g crude drug/kg/; Former invention eye drop group only splashes into administration 0.012g crude drug/kg/.According to eye inflammation, show: shed tears, secretions thickness, conjunctival congestion, edema corneal edema.Press Ministry of Public Health bureau of drug administration " study of tcm new drug guide " they " eye irritant reaction standards of grading ", each time period eye conjunctiva degree of inflammation is marked.Experimental result: in Table 1
Table 1 is the impact with the conjunctiva inflammation on rabbit due to Oleum Tiglii
Compare * * P<0.01 with model group; With former invention eye drop group than △ P<0.05.
Result shows: gold leaf eye drop group of the present invention and former invention eye drop group 6h after causing inflammation can obviously suppress eye inflammation, with matched group, utmost point significant difference (P<0.01) is relatively arranged; The heavy dose of significant difference (P<0.05) of having compared with former invention eye drop group of organizing of gold leaf eye drop of the present invention.Visible, gold leaf eye drop group of the present invention is stronger than the effect of former invention eye drop group treatment eye conjunctivitis.
Two, on the impact of rabbit eyes Bulbar conjunctiva microcirculation
1, animal: rabbit, male and female have concurrently, body weight 1.8～2.2kg.
2, medicine: former invention eye drop group; Large, medium and small three the dosage groups of gold leaf eye drop of the present invention.
Experimental technique
Adopt rabbit eyes conjunctiva blood capillary fluorimetry.50 of rabbit, male and female half and half, body weight 1.8～2.2kg, be divided into 5 groups at random, 10 every group.Matched group only splashes into normal saline 150 μ l/; Large, medium and small three the dosage groups of gold leaf eye drop group of the present invention only splash into respectively administration 0.012,0.006,0.003g crude drug/kg/; Former invention eye drop group only splashes into administration 0.012g crude drug/kg/.Successive administration 3d, every day 1 time, 1h after the last administration, the uranin normal saline solution 1ml/kg (being equivalent to fluorescein 100mg/kg) of family's rabbit ear vein injection 10%, record rabbit conjunctival and the fluorescence time occurs.Experimental result: in Table 2
The impact of table 2 on the rabbit eyes Bulbar conjunctiva microcirculation
Compare * * P<0.01 with matched group; With former invention eye drop group than △ P<0.05.
Result shows: gold leaf eye drop group of the present invention and former invention eye drop group are obviously accelerated rabbit eyes Bulbar conjunctiva microcirculation blood flow, promote the ocular blood circulation, have compared utmost point significant difference (P<0.01) with matched group; The heavy dose of significant difference (P<0.05) of having compared with former invention eye drop group of organizing of gold leaf eye drop of the present invention.Visible, the effect that gold leaf eye drop group of the present invention is improved the eye Bulbar conjunctiva microcirculation than former invention eye drop group is strong.
Three, the impact of xylol induced mice auricle edema
Experiment material
1, animal: Kunming mouse, male and female half and half, body weight 18～22g.
2, medicine: former invention eye drop group; Large, medium and small three the dosage groups of gold leaf eye drop of the present invention.
Experimental technique
50 of Kunming mouses, male and female half and half, body weight 18～22g, be divided into 5 groups at random, 10 every group.Matched group only splashes into normal saline 50 μ l/; Large, medium and small three the dosage groups of gold leaf eye drop group of the present invention only splash into respectively administration 0.04,0.02,0.01g crude drug/kg/; Former invention eye drop group only splashes into administration 0.04g crude drug/kg/.Successive administration 3d, every day 1 time, after the 3d administration, be coated with dimethylbenzene 0.01ml simultaneously on the left ear of mice two sides and cause inflammation, cause scorching 30min post-tensioning neck and put to death mice, along the auricle baseline, cut two ears, accurate its left and right two auricle weight that claim, with the swelling degree of left and right auricle weight difference value representation mice ear inflammation.Experimental result: in Table 3
The impact of table 3 on swelling due to Mice Auricle dimethylbenzene
Compare * * P<0.01 with matched group; With former invention eye drop group than △ P<0.05.
Result shows: gold leaf eye drop group of the present invention and former invention eye drop group can obviously suppress the swelling of dimethylbenzene induced mice auricle, the utmost point significant difference of having compared with matched group (P<0.01); The heavy dose of significant difference (P<0.05) of having compared with former invention eye drop group of organizing of gold leaf eye drop of the present invention.Visible, gold leaf eye drop group of the present invention is stronger than the antiinflammatory action of former invention eye drop group.
Four, on the impact of mouse peritoneal capillary permeability
Experiment material
1, animal: Kunming mouse, male and female half and half, body weight 18～22g.
2, medicine: former invention eye drop group; Large, medium and small three the dosage groups of gold leaf eye drop of the present invention.
Experimental technique
50 of Kunming mouses, male and female half and half, body weight 18～22g, be divided into 5 groups at random, 10 every group.Matched group only splashes into normal saline 50 μ l/; Large, medium and small three the dosage groups of gold leaf eye drop group of the present invention only splash into respectively administration 0.04,0.02,0.01g crude drug/kg/; Former invention eye drop group only splashes into administration 0.04g crude drug/kg/.Successive administration 3d, every day 1 time, after 3d administration 1h by mouse tail vein injection 0.5% Yi Wensilan normal saline solution 0.1ml/10kg, 20min pneumoretroperitoneum in interval is only injected 0.6% acetum 0.2ml/ again, broken end sacrificed by exsanguination mice after 20min, cutting abdominal cavity open rinses repeatedly with the 6ml normal saline, and collection eluate, add normal saline to adjust volume to 10ml, the centrifugal 15min of 3000r/min, get supernatant with 722 spectrophotometers in the colorimetric determination of 590nm place, find every mouse peritoneal and infiltrate amount of dye on standard curve.Experimental result: in Table 4
The impact of table 4 mouse peritoneal capillary permeability
Compare * * P<0.01 with matched group; With former invention eye drop group than △ P<0.05.
Result shows: the mouse peritoneal capillary permeability due to gold leaf eye drop group of the present invention and former invention eye drop group Dichlorodiphenyl Acetate increases has obvious inhibitory action, the utmost point significant difference of having compared with matched group (P<0.01); The heavy dose of significant difference (P<0.05) of having compared with former invention eye drop group of organizing of gold leaf eye drop of the present invention.Visible, gold leaf eye drop group of the present invention than former invention eye drop group antiinflammatory action strong.
Five, on the impact of trinitro-chlorobenzene induced mice ear delayed hypersensitivity
Experiment material
1, animal: Kunming mouse, male and female half and half, body weight 18～22g.
2, medicine: former invention eye drop group; Large, medium and small three the dosage groups of gold leaf eye drop of the present invention.
Experimental technique
50 of Kunming mouses, male and female half and half, body weight 18～22g, be divided into 5 groups at random, 10 every group.Matched group only splashes into normal saline 50 μ l/; Large, medium and small three the dosage groups of gold leaf eye drop group of the present invention only splash into respectively administration 0.04,0.02,0.01g crude drug/kg/; Former invention eye drop group only splashes into administration 0.04g crude drug/kg/.Successive administration 7d, every day 1 time.In administration second day mouse part skin unhairing, 1h after administration in the 3rd day, with 2% trinitro-chlorobenzene ethanol 0.05ml/ only, be applied in mouse web portion unhairing position skin, the next day, strengthen once with method, matched group replaces 2% trinitro-chlorobenzene ethanol with ethanol, 1h after the 7th day medicine of administration, being applied in the mouse right ear two sides with 0.5% trinitro-chlorobenzene Fructus Canarii albi fluid 0.02ml is attacked, after 24h, mice draws neck to put to death, cut mice left and right two ears, lay with card punch the auricle that diameter is 8mm, precise weighing, using mice left and right auricle weight difference as mouse ear delayed hypersensitivity intensity.Experimental result: in Table 5
The impact of table 5 on trinitro-chlorobenzene induced mice ear delayed hypersensitivity
Compare * * P<0.01 with matched group; With former invention eye drop group than △ P<0.05.
Result shows: gold leaf eye drop group of the present invention and former invention eye drop group can significantly suppress trinitro-chlorobenzene induced mice delayed hypersensitivity, with matched group, utmost point significant difference (P<0.01) are relatively arranged; Significant difference (P<0.05) that gold leaf eye drop heavy dose of the present invention is organized and former invention eye drop group has been compared.Visible, the effect that gold leaf eye drop group of the present invention improves immunity than former invention eye drop group is strong.
Six, Turnover of Mouse Peritoneal Macrophages is engulfed the impact of chicken red blood cell ability
Experiment material
1, animal: Kunming mouse, male and female half and half, body weight 18～22g.
2, medicine: former invention eye drop group; Large, medium and small three the dosage groups of gold leaf eye drop of the present invention.
Experimental technique
50 of Kunming mouses, male and female half and half, body weight 18～22g, be divided into 5 groups at random, 10 every group.Matched group only splashes into normal saline 50 μ l/; Large, medium and small three the dosage groups of gold leaf eye drop group of the present invention only splash into respectively administration 0.04,0.02,0.01g crude drug/kg/; Former invention eye drop group only splashes into administration 0.04g crude drug/kg/.Successive administration 7d, every day 1 time, after last administration 2h, the chicken red blood cell 0.4ml of every mouse peritoneal injection 5%, after 12 hours, the de-cervical vertebra of mice is put to death, face upward position and be fixed in the Mus plate, the sterilization abdominal part, cut off skin, through intraperitoneal injection of saline 2ml, rotate fixing head 1min, then extract peritoneal fluid 1ml, drip and be applied on microscope slide, every 0.2ml, be placed in 37 ℃ of incubator incubation 30min, take out slide, drop into rinsing in normal saline, dry, with the fixing 5min of acetone-methanol solution (1: 1), again with 4% Ji Mu Sa-Rui Teshi liquid dyeing 5min, use the distilled water rinsing, dry.Count under oily mirror, and calculate the phagocytic index that peritoneal macrophage is engulfed chicken red blood cell.Chicken red blood cell sum/200 macrophage experimental results of phagocytic index=engulfed: in Table 6
Table 6 is engulfed the impact of chicken red blood cell ability on Turnover of Mouse Peritoneal Macrophages
Compare * * P<0.01 with matched group; With former invention eye drop group than △ P<0.05.
Result shows: gold leaf eye drop group of the present invention and former invention eye drop group can obviously strengthen the effect of macrophage phagocytic function, have compared utmost point significant difference (P<0.01) with matched group; The heavy dose of significant difference (P<0.05) of having compared with former invention eye drop group of organizing of gold leaf eye drop of the present invention.Visible, the effect that gold leaf eye drop group of the present invention improves immunity than former invention eye drop group is strong.
Experimental result: gold leaf eye drop group of the present invention and former invention eye drop group can obviously suppress eye inflammation; Obviously accelerate rabbit eyes Bulbar conjunctiva microcirculation blood flow, promote the ocular blood circulation; Obviously suppress the swelling of dimethylbenzene induced mice auricle; Mouse peritoneal capillary permeability due to Dichlorodiphenyl Acetate increases obvious inhibitory action; Significantly suppress trinitro-chlorobenzene induced mice delayed hypersensitivity; Obviously strengthen the effect of macrophage phagocytic function.
Conclusion: gold leaf eye drop of the present invention than former invention eye drop to improve the pharmacological actions such as microcirculation, antiinflammatory, raising immunity of organisms and treatment conjunctiva inflammation strong.Therefore, gold leaf eye drop of the present invention is than former invention eye drop heat-clearing and toxic substances removing clinically, and the effect of moving back red detumescence is strong.
The acute toxicity testing result shows: by gold leaf eye drop Cmax of the present invention, maximum volume gastric infusion, in 24h, successive administration is 3 times, every minor tick 4h, and accumulation medicine total amount reaches 0.28g crude drug/kg, is equivalent to 210 times of clinical plan consumption.After administration in 7d, mice is movable, feed, excretion are all normal, well-grown, and the hair color light, its average body weight average increases with the prolongation of test period.Dissect every mice perusal heart, liver, spleen, lung, kidney, brain, thymus, adrenal gland, stomach, intestinal etc. after 8d puts to death and all do not find color and paramophia.Show that gold leaf eye drop of the present invention is without acute toxic reaction.
The long term toxicity test result shows: gold leaf eye drop component of the present invention is that basic, normal, high dosage is respectively 0.04,0.08,0.16g crude drug/kg/d, be equivalent to 30,60,120 times of clinical dosage, after gastric infusion 12 weeks, gold leaf eye drop of the present invention all affects without obvious general status, hematological indices, the blood parameters of animal, and system dissection, organ coefficient and histopathological examination be no abnormal pathological change also.Drug withdrawal also has no obvious change in 2 weeks.Gold leaf eye drop of the present invention, in long term toxicity test, is not found overt toxicity reaction and delayed toxicity reaction.Visible, gold leaf eye drop non-toxic reaction of the present invention, long-term prescription is safe and reliable.
Embodiment 1:
Prescription:
Flos Lonicerae 100g Folium Mori 30g Flos Chrysanthemi Indici 30g.
Preparation method is:
Above three flavors, extracting honeysuckle adds ethanol 100ml, soak and within 24 hours, press appendix I0 percolation of Chinese Pharmacopoeia version in 2000, with 10 times of amounts of 75% ethanol, carry out percolation, percolation speed is 1～3ml/ minute. kilogram, collect percolate, residue pressed liquor and percolate merge, and standing 24 hours, filter, decompression recycling ethanol to 50 ℃ records relative density and is 1.1, standby, medicinal residues and Folium Mori, Flos Chrysanthemi Indici decocts with water twice, add for the first time 10 times of amounts of water, decoct 30 minutes, collect distillate 60-100ml, add for the second time 8 times of amounts of water, decoct 30 minutes, merge decocting liquid twice, filter, being concentrated into 25 ℃, to record relative density be 1.1-1.2, add ethanol to make to reach 65% containing the alcohol amount, cold preservation 24 hours, filter, it is 1.1 that filtrate recycling ethanol to 50 ℃ records relative density, add ethanol to make to reach 75% containing the alcohol amount, standing 24 hours, filter, it is 1.1 that filtrate recycling ethanol to 50 ℃ records relative density, merge extracted twice filtrate and distillate, add greening sodium 6g, ethyl hydroxybenzoate 0.2g, be stirred to dissolve, adding distil water is to 1000ml, reconciling pH with 5% sodium hydroxide solution is 6.5-7.5, add again 0.2% active carbon to boil 10 minutes, filter, packing, sterilizing, obtain eye drop.
Claims (1)
1. the preparation method for the eyedrops of acute conjunctivitis, is characterized in that the crude drug weight proportion of described eyedrops is: Flos Lonicerae 100g Folium Mori 30g Flos Chrysanthemi Indici 30g;
Preparation method is: above three flavors, extracting honeysuckle adds ethanol 100ml, soak and within 24 hours, press appendix I 0 percolation of Chinese Pharmacopoeia version in 2000, with 10 times of amounts of 75% ethanol, carry out percolation, percolation speed is 1～3ml/ minute. kilogram, collect percolate, residue pressed liquor and percolate merge, and standing 24 hours, filter, decompression recycling ethanol to 50 ℃ records relative density and is 1.1, standby, medicinal residues and Folium Mori, Flos Chrysanthemi Indici decocts with water twice, add for the first time 10 times of amounts of water, decoct 30 minutes, collect distillate 60-100ml, add for the second time 8 times of amounts of water, decoct 30 minutes, merge decocting liquid twice, filter, being concentrated into 25 ℃, to record relative density be 1.1-1.2, add ethanol to make to reach 65% containing the alcohol amount, cold preservation 24 hours, filter, it is 1.1 that filtrate recycling ethanol to 50 ℃ records relative density, add ethanol to make to reach 75% containing the alcohol amount, standing 24 hours, filter, it is 1.1 that filtrate recycling ethanol to 50 ℃ records relative density, merge extracted twice filtrate and distillate, add sodium chloride 6g, ethyl hydroxybenzoate 0.2g, be stirred to dissolve, adding distil water is to 1000ml, reconciling pH with 5% sodium hydroxide solution is 6.5-7.5, add again 0.2% active carbon to boil 10 minutes, filter, packing, sterilizing, obtain eye drop.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101751855A CN103211869B (en) | 2013-05-13 | 2013-05-13 | Traditional Chinese medicine eye drops used for treating acute conjunctivitis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101751855A CN103211869B (en) | 2013-05-13 | 2013-05-13 | Traditional Chinese medicine eye drops used for treating acute conjunctivitis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103211869A CN103211869A (en) | 2013-07-24 |
| CN103211869B true CN103211869B (en) | 2013-12-04 |
Family
ID=48810255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101751855A Active CN103211869B (en) | 2013-05-13 | 2013-05-13 | Traditional Chinese medicine eye drops used for treating acute conjunctivitis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103211869B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105031457A (en) * | 2015-09-20 | 2015-11-11 | 南京正宽医药科技有限公司 | Eye drops for treating conjunctivitis |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520552B (en) * | 2013-10-25 | 2015-04-22 | 青岛市中心医院 | Traditional Chinese medicine composition for treating acute conjunctivitis and preparation method thereof |
| CN105106318B (en) * | 2015-09-15 | 2018-10-19 | 北京市眼科研究所 | A kind of Chinese medicine composition and preparation method thereof for treating xerophthalmia |
| CN105560891A (en) * | 2016-01-13 | 2016-05-11 | 成都大学 | Traditional Chinese medicine eye drops containing borneol and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1100953A (en) * | 1994-06-14 | 1995-04-05 | 咸阳市第三制药厂 | Eyedrops |
| CN1943630A (en) * | 2005-10-08 | 2007-04-11 | 曾雄辉 | Eye medicine for preventing and treating conjunctivitis and keratitis and its preparing method |
-
2013
- 2013-05-13 CN CN2013101751855A patent/CN103211869B/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105031457A (en) * | 2015-09-20 | 2015-11-11 | 南京正宽医药科技有限公司 | Eye drops for treating conjunctivitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103211869A (en) | 2013-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103211869B (en) | Traditional Chinese medicine eye drops used for treating acute conjunctivitis and preparation method thereof | |
| CN102416106B (en) | Chinese medicinal composition for treating middle-aged and senile eye disease and preparation method thereof | |
| CN103301146B (en) | Traditional Chinese medicine monomer combination capable of resisting oxidation and improving eyeground blood circulation | |
| KR102099520B1 (en) | Chinese medicine composition to treat diabetic retinopathy | |
| CN102319398B (en) | Blood-nourishing and eyesight-improving Chinese medicinal composition and preparation method thereof | |
| CN102526423A (en) | Medicine composition for treating ischemic heart disease | |
| CN105125984B (en) | A kind of aqueous Chinese medicine plaster for external application for treating infantile cough | |
| CN102188520B (en) | Traditional Chinese medicine composition for the treatment of cerebral ischemia and application thereof | |
| CN101361892B (en) | Traditional Chinese medicine formulation for treating cataract and preparation method thereof | |
| CN102293847B (en) | Chinese medicinal composition for treating constipation, acne and hyperlipidemia, and preparation method | |
| CN102335231A (en) | Chinese medicinal moisturizing cream for treating chloasma as well as preparation method and application thereof | |
| CN1853681A (en) | Medicine for treating nervous prostration and improving sleep | |
| CN113101339B (en) | Decoction for treating chronic liver injury and preparation method and application thereof | |
| CN103784579A (en) | Traditional Chinese medicinal composition for inflammation diminishing, eyesight improving and pain relieving, and preparation method thereof | |
| CN107982484A (en) | Treat Chinese medicinal compound extract of diabetic retinopathy and its preparation method and application | |
| CN103463244A (en) | Method for extracting blood sugar lowering substance from China roses and application of blood sugar lowering substance | |
| CN100500174C (en) | Medicine composition used for lowering blood-sugar, preparation method and use thereof | |
| CN103006831A (en) | Blood platelet raising capsules, namely Chinese herbal combination, and preparation method of capsules | |
| CN103566227B (en) | A kind of Chinese medicine composition preventing and treating type 2 diabetes mellitus and preparation method thereof | |
| CN102078509A (en) | Traditional Chinese medicine preparation for treating ophthalmorrhagia and preparation method thereof | |
| CN1857531A (en) | Recipe, preparing process and application of Chinese medicine preparation for treating diabetic retinopathy | |
| CN104306546A (en) | A traditional Chinese medicine composition used for treating optic atrophy, and decoctions, pills and powder of the composition | |
| CN103549072A (en) | Vital energy-benefiting brain-boosting tea and preparation method thereof | |
| CN109394838A (en) | A kind of pharmaceutical composition for treating senile macular degeneration | |
| CN104998108A (en) | Traditional Chinese medicine composite for treating xerophthalmia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 710400 Ma Zhao section 1420, national highway 108, Zhouzhi County, Xi'an City, Shaanxi Province Patentee after: Zhouzhi Qingbao Pharmaceutical Co.,Ltd. Address before: Room A1604, Cross High Tech Building, Xiyang Village, Weiyang West Road, Xianyang City, Shaanxi Province, 712000 Patentee before: SHAANXI LIZHONG PHARMACEUTICAL Co.,Ltd. |
|
| CP03 | Change of name, title or address |